Post hoc analysis of 940 patients with stage III colon cancer: postoperative ctDNA positivity predicted worse DFS (aHR 6.12). Celecoxib was associated with better DFS in ctDNA-positive patients (aHR 0.61) but not ctDNA-negative ones; interaction not significant.
Secondary analysisn = 940
Zhang et al. Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Clinical Trial